Plus Therapeutics to Present New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting Page 1

Company presents new data highlighting progress in its therapeutic program for recurrent glioblastoma (rGBM)

AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiation therapeutics with advanced platform technologies for cancers of the central nervous system, will present data at the Congress of Neurological Surgeons (CNS) 2024 Annual Meeting, September 28 through October 2 in Houston, Texas.

Presentation: